Sucroferric Oxyhydroxide Improves Phosphorus Control

Share this content:
After switching to sucroferric oxyhydroxide, a higher proportion of patients achieved in-range serum phosphorus levels.
After switching to sucroferric oxyhydroxide, a higher proportion of patients achieved in-range serum phosphorus levels.
The following article is part of conference coverage from Kidney Week 2017 in New Orleans hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2017.

NEW ORLEANS—Hemodialysis patients with hyperphosphatemia were more likely to achieve in-range serum phosphorus levels 2 years after switching to sucroferric oxyhydroxide from another phosphate binder, investigators reported at the American Society of Nephrology's Kidney Week 2017 meeting. They also experienced a clinically significant decline in pill burden.

Stuart M. Sprague, MD, of NorthShore University HealthSystem in Chicago, and colleagues studied 241 adult Fresenius Kidney Care HD patients who had switched to sucroferric oxyhydroxide during January 1, 2014 to March 31, 2015 and continued on the phosphate binder for 2 years. Patients had a mean age of 54 years and dialysis vintage of 57 months at baseline. Prior to switching, 67% patients were taking sevelamer and 26 % calcium acetate.

Before switching, subjects had a mean serum phosphorus of 6.7 mg/dL (15.8% had serum phosphorus levels 5.5 mg/dL or less). At 2 years, mean serum phosphorus decreased to 6.0 mg/dL, with 44.1% of subjects having a phosphorus of less than 5.5 mg/dL at 2 years, a 179% increase from baseline.

The mean pill burden decreased from 9.4 pills per day at baseline (3 months prior to switching to sucroferric oxyhydroxide) to 4.4–4.9 pills per day at 2 years (a decrease of 48%–53% from baseline).

Fresenius Medical Care North America funded the study.

Visit Renal & Urology News' conference section for continuous coverage from Kidney Week 2017.


Reference

Sprague SM, Parameswaran V, Ficociello LH, et al. Two year follow up on chronic hemodialysis (HD) patients prescribed sucroferric oxyhydroxide as part of routine care. Data presented in poster format at Kidney Week 2017 in New Orleans (Oct. 31 to Nov. 5). Abstract TH-PO1030

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters